CLRB
Companies
NASDAQ
Cellectar Biosciences Inc.
Health Care
$0.37
+$0.07 (+21.83%)
Price Chart
Overview
About CLRB
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Market Cap
$119.4M
Volume
252.8K
Avg. Volume
456.6K
P/E Ratio
-0.093604244
Dividend Yield
0.00%
Employees
26.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.93
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CLRB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025